

Myeloid Neoplasms

2011 Reporting Requirements and CSv02.03.02 Standard Treatment Guidelines

FCDS 2011 Educational Webcast Series

November 2, 2011

Steven Peace, CTR

Presentation Outline

- Overview – Incidence/Mortality, Signs and Symptoms, Risk Factors
- WHO 2008 Classification of Myeloid Neoplasm – 6 Groups
- Characteristics of Major Classification Groups
- Characteristics of Specific Myeloid Neoplasm
- Standard Treatment Guidelines for Specific Conditions
- Hematopoietic Multiple Primary and Histology Coding Rules Refresher
- Collaborative Stage Data Collection System (CSv02.03.02)
- 2011 FCDS Required C.S. Site Specific Factors
- Text Documentation



Overview of the Myeloid Neoplasms

Incidence and Mortality

Signs and Symptoms

Risk Factors

Myeloid Neoplasm Characteristics

- 2011 estimates in the United States
 - 44,600 new leukemia cases – All types
 - 12,950 new AML cases
 - 5,150 new CML cases
 - 6,200 other leukemia Cases
 - 9,050 AML deaths and 270 CML deaths



- No published data for myeloproliferative disorders – new cases/deaths
- No published data for myelodysplastic syndrome – new cases /deaths

- 2011 estimates in the State of Florida
 - 2079 new leukemia cases – All types
 - 705 new AML cases
 - 244 new CML cases
 - 1131 other leukemia Cases
 - 634 AML deaths and 63 CML deaths



Source: American Cancer Society Cancer Facts and Figures
Florida Cancer Data System

Risk Factors

- Exposure to ionizing radiation including medical radiation



- Exposure to cytotoxic chemotherapeutic agents

- Family history



- Cigarette smoking

- Benzene exposure – industrial chemicals, gasoline, cigarettes



5


Proliferation and Differentiation

- Regulation of proliferation
- Regulation of differentiation
- Both affect development along cell

- Turn on/Turn off

- Growth factors
- Genes (including mutations)
- Proteins

- Oncogenesis – becoming malignant



6

Hematopoietic stem cells give rise to two major progenitor cell lineages, myeloid and lymphoid progenitors
Regenerative Medicine, 2006. <http://www.dentalarticles.com/images/hematopoiesis.png>

Signs and Symptoms

- Fatigue
- Paleness
- Weight loss
- Repeated infections
- Fever
- Easy bruising
- Nosebleeds and other hemorrhage



<http://www.allleukemia.com/leukemia-symptoms-in-adults.html>



<http://www.surgical-blog.com/symptoms-of-acute-myeloid-leukemia->

7

Signs and Symptoms

- AML usually has sudden onset of symptoms
- CML usually progresses slowly with 4-5 years lapsing prior to transformation to acute phase
- Other myeloid neoplasms have varying courses of disease
 - Some have more predictable disease progression
 - Others may remain in chronic phase for many years
 - A few rapidly advance to AML

8

Work Up and Confirmation Testing

- CBC
- Peripheral Blood Smear
- Bone Marrow Aspirate
- Bone Marrow Biopsy


- Histology/Morphology
- Cytochemistry
- Flow Cytometry (Immunophenotype)
- Molecular Genetic Studies



9

Myeloid Neoplasm Disease Course

- Initial Diagnosis is based on abnormal CBC and symptoms
- Many are chronic and relatively asymptomatic
- Diagnosis of Inclusion and Exclusion
- Specific types tend to stay in chronic phase
- Some types predictably progress to acute (blastic) phase



10

Reclassification Myeloid Conditions

- Before 2000 myelodysplastic and myeloproliferative conditions were felt to be pre-leukemia blood-disorders – not malignant
- Scientific evidence confirmed **single cell line affected** – met criteria
- ICD-O-3 “behavior” changed from /1 to /3
- WHO in 2008 reclassified again into six new categories
- **Diagnosis and treatment occur outside hospital in office only**
- Florida and ALL other states are underreporting these cases

11

Myeloid Neoplasm Research

- National Institutes of Health
- National Heart, Lung and Blood Institute
- National Cancer Institute
- Pharmaceutical company studies
- Device company funded studies
- Public/Private collaborations



12

Myeloid Neoplasm Research



13

Myeloid Neoplasm Research

National Heart, Lung and Blood Institute



10-22-2009



14

Myeloid Neoplasm Research

- **NHLBI - Division of Blood Diseases and Resources**
- The Division of Blood Diseases and Resources (DBDR) is part of the National Heart, Lung, and Blood Institute (NHLBI), one of 27 institutes and centers at the National Institutes of Health (NIH). DBDR supports research on the causes, prevention, and treatment of **nonmalignant blood diseases, including anemias, sickle cell disease, and thalassemia; premalignant processes such as myelodysplasia and myeloproliferative disorders**; hemophilia and other abnormalities of hemostasis and thrombosis; and immune dysfunction. Funding encompasses a broad spectrum of research ranging from basic biology to medical management of blood diseases.
- **BLOOD DISEASES BRANCH**
- The Blood Diseases Branch supports research and training programs focusing on a wide variety of blood diseases that include sickle cell disease (SCD), thalassemia, **Fanconi anemia, Diamond-Blackfan anemia and other aplastic anemias** as well as outcomes-related research.
- **THROMBOSIS AND HEMOSTASIS BRANCH**
- This Branch supports research and training programs on basic research, clinical studies, and technology development in hemostasis, thrombosis, and endothelial cell biology. The main focus is on understanding the pathogenesis of both arterial and venous thrombosis in order to improve diagnosis, prevention, and treatment of thrombosis in heart attack, stroke, and peripheral vascular diseases. A major goal is to find additional platelet inhibitors, anticoagulants, and fibrinolytic agents that will improve specificity and reduce side effects when used in treating thrombotic and thromboembolic disorders. Specialized Centers of Clinically Oriented Research (SCCORS) support collaborative studies on hemostatic and thrombotic disorders.
- Finding effective treatments for bleeding disorders is another priority. The Branch supports research on hemophilia and von Willebrand Disease as well as immune disorders such as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and systemic lupus erythematosus. **Emerging areas of interest are gene transfer, clinical proteomics, inflammation and thrombosis, stroke, coagulation activation, autoimmune disease, and thrombotic complications of obesity, diabetes, and cancer.**

15

Myeloid Neoplasm Research

- **NHLBI - Division of Blood Diseases and Resources**
- **TRANSFUSION MEDICINE AND CELLULAR THERAPEUTICS BRANCH**
- This Branch supports research and research training in transfusion medicine, **stem cell biology and disease, clinical cellular medicine**, and blood supply adequacy and safety. Research focus is on the use, safety, and availability of blood and blood components for transfusion and cellular therapies. Research areas include transmission of disease, non-infectious complications of transfusions, immunobiology, cell biology and disease, novel cell-based therapies, **hematopoietic stem cell transplantation**, and overall product availability. The Branch develops programs for basic and clinical research related to normal and abnormal cellular biology and pathology. It also collaborates with governmental, private sector, and international organizations to improve the safety and availability of the global supply of blood and blood components.
- **The Branch also supports two clinical research networks to promote efficient comparison of innovative treatment strategies. The Bone Marrow Transplant Clinical Trials Network (BMTCTN) supports trials for patients undergoing blood or marrow transplantation.** The Transfusion Medicine/Hemostasis Clinical Trials Network (TMHCTN) supports trials for patients with hemostatic disorders, such as idiopathic thrombocytopenia and thrombotic thrombocytopenic purpura. Specialized Centers of Clinically Oriented Research support collaborative studies on transfusion biology and medicine.

16

Myeloid Neoplasm Research

- WHO no longer classifies Myeloproliferative Disorders
- All are now Myeloproliferative Neoplasms
- Initial Reclassification 2000
- Updated Reclassification 2008
- New Registry Rules 2010




17

World Health Organization 2008 Classification of Myeloid Neoplasms

2008 - WHO Classification of Tumors

- 2008 – WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th edition, October 2008






19

WHO Classification of Myeloid Neoplasms

Incorporates:


- Morphology
- Stage of differentiation
- Immunophenotype
- Genotypic features
- Clinical features



Myeloid – 6 Classification Groups

- Myeloproliferative Neoplasms
- Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
- Myelodysplastic/Myeloproliferative Neoplasms
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia and Related Precursor Neoplasms
- Acute Leukemias of Ambiguous Lineage

21



22


Myeloproliferative Neoplasms

Table B1: Myeloproliferative Neoplasms

| WHO Preferred Term | ICD-O-3 |
|---|---------|
| Chronic eosinophilic leukemia, NOS (CEL) | 9964/3 |
| Chronic myelogenous leukemia (CML), BCR-ABL1+ (Ph+) | 9875/3 |
| Chronic neutrophilic leukemia (CNL) | 9963/3 |
| Cutaneous mastocytosis (SM) | 9740/1 |
| Essential thrombocythemia (ET) | 9962/3 |
| Mast cell leukemia ((SM) | 9742/3 |
| Mast cell sarcoma (SM) | 9740/3 |
| Myeloproliferative neoplasm, unclassifiable (MPN-U) | 9975/3 |
| Polycythemia vera (PV) | 9950/3 |
| Primary myelofibrosis (PMF) | 9961/3 |
| Systemic mastocytosis (SM) | 9741/3 |


23

Interrelationship of MPNs




Spivak, J. Ann Intern Med; 152:300


Framework for MPNs



Philadelphia Chromosome



BCR ABL Fusion Gene



27

Molecular Defects in MPNs

Table. The Chronic Myeloproliferative Disorders

| Disease | Molecular Defect* |
|--|---|
| Chronic myelogenous leukemia | <i>BCR-ABL</i> |
| Chronic eosinophilic leukemia and the hypereosinophilic syndrome | <i>FIP1L1-PDGFRB</i> |
| Chronic neutrophilic leukemia | <i>BCR-ABL</i> p230 |
| Chronic myelomonocytic leukemia | <i>TEL-PDGFRB</i> |
| Systemic mastocytosis | <i>KIT</i> D816V |
| Polycythemia vera | <i>JAK2</i> V617F (~92% positive) <i>JAK2</i> exon 12 mutations (3% positive) |
| Essential thrombocytosis | <i>JAK2</i> V617F (~50% positive) <i>MPL</i> W515L/K (~3% positive) <i>MPL</i> K39N |
| Primary myelofibrosis | <i>JAK2</i> V617F (~50% positive) <i>MPL</i> W515L/K (~14% positive) |

28

Spivak, J. *Ann Intern Med*, 2010; 152:300

CML as Our Primary Example

Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR ABL+
Chronic Myeloid Leukamia

Chronic Myelogenous Leukemia

- Today known as Chronic Myelogenous Leukemia BCR-ABL1 +
- Previously known as Chronic Granulocytic Leukemia
- Diagnostic work up should include bone marrow aspirate cytogenetics, fluorescent in situ hybridization (FISH) and quantitative polymerase chain reaction (QPCR).
- Most patients with CML are found to be Philadelphia chromosome positive (Ph⁺) or BCR-ABL positive.
- BCR-ABL is a chromosomal abnormality that can be detected by QPCR.

Chronic Myelogenous Leukemia

Initial Indicators:


- The white blood cell count can range from ~25,000/L to >300,000/L.
- Mild anemia is common.
- Thrombocytosis is present in ~30 to 50% of patients, and the platelet count can exceed 1,000,000/L.

Peripheral Blood Smear:

- The blood smear in CML is very characteristic.
- There is a marked granulocytosis including all stages of granulocytic maturation, from blasts to segmented neutrophils.
- There is a predominance of more mature forms, from myelocytes to segmented neutrophils.
- Myeloblasts are typically only 1 to 2% of WBCs and are always <10% in the chronic phase.
- **Basophils** are *always* increased in number and usually in the percentage of WBC.

31

Chronic Myelogenous Leukemia



32

Figure 14–1 Chronic myelogenous leukemia blood smear. All stages of granulocyte maturation are present, with a predominance of mature forms; several basophils are present.

Chronic Myelogenous Leukemia

Table 14-1

Characteristics of Chronic Myelogenous Leukemia (Chronic Phase)

| |
|--|
| <p>Blood:</p> <ul style="list-style-type: none"> • Granulocytosis • Full range of granulocyte precursors • Predominance of myelocytes and segmented neutrophils • Myeloblasts typically ~1–2%; always <10% • Basophilia • Thrombocytosis common <p>Bone Marrow:</p> <ul style="list-style-type: none"> • Hypercellular • Granulocytic hyperplasia (increased M:E ratio) • Increased megakaryocytes, particularly small megakaryocytes • Mild fibrosis in one-third of patients <p>Splenomegaly</p> <p>Decreased LAP score</p> <p>Philadelphia chromosome [t(9;22)] and/or <i>bcr/abl</i> rearrangement</p> <p>Elevated serum cobalamin (vitamin B₁₂) and uric acid</p> |
|--|


M:E = myeloid to erythroid; LAP = leukocyte alkaline phosphatase.

33

Source: National Cancer Institute - PDQ Hematology

Chronic Myelogenous Leukemia

- Directly associated with translocation of specific area of the Philadelphia chromosome (Ph) resulting in juxtaposition of *abl* (Abelson leukemia virus) gene on chromosome 9 fusing with the *bcr* (breakpoint cluster region) on chromosome 22 [aka: t(9;22)]
- This is referred to as the *bcr/abl* fusion gene] found in nearly 100% of all CML patients



34


Chronic Myelogenous Leukemia

- Philadelphia chromosome [t(9;22)(q34;q11)] present in ~85 to 95% of cases standard cytogenetic analysis (QPCR)
- Variant cytogenetic abnormality present in ~5 to 10% of cases.
- Occasionally, no Philadelphia chromosome or other detectable abnormality is noted by RT PCR, but a t(9;22) is detected by fluorescence in situ hybridization (FISH)
- Other bcr/abl rearrangement is detected by molecular test

35

Chronic Myelogenous Leukemia

If there is no Philadelphia chromosome or variant by standard cytogenetics (standard cytogenic analysis or RT PCR), and no evidence of a bcr/abl rearrangement is identified by FISH or other molecular tests, then the diagnosis is not CML!



36

Chronic Myelogenous Leukemia Treatment Recommendations

- Treatment by Phase
- Chronic Phase: 3 month, 6 month, 12 month F/U
- Accelerated and Blast Phase

37

Treatment by Phase

- Based on the percent of blasts in the peripheral blood, patients are diagnosed as:
 - **Chronic Phase (<10% blasts)**
 - **Accelerated phase (10-19% blasts)**
 - **Blast phase (>20% blasts)**
- Some patients progress directly from chronic phase to blast crisis, without an intermediate accelerated phase.
- Some patients never progress to more advanced phase.

38

Chronic Phase CML: Recommendations

- **Ph⁺ chronic phase CML is typically treated with a tyrosine kinase inhibitor (TKI).**
- **TKIs include imatinib, nilotinib or dasatinib.**
- All TKIs are given orally so there will be no “administration” documentation rather the patient will be given prescriptions
- Other treatment options include clinical trial or Hematopoietic Stem Cell Transplant [HSCT].

39

Tyrosine Kinase Inhibitor (TKI).

- Imatinib (Gleevec®) 400 mg po daily (with a meal and large glass of water)
- Nilotinib (Tasigna®) 300 mg po twice daily (no food 2 hours before or 1 hour after dose)
- Dasatinib (Sprycel®) 100mg po daily (with or without a meal)
- Patients are typically asked during follow up appointments if they are taking meds as prescribed or to bring back their pill bottles so the pills can be counted to determine compliance.

40

Chronic Phase CML – Follow-up

- Patients are evaluated for a cytogenetic response
- Treatment is based on response
 - Complete Response – no Ph⁺ positive metaphases
 - Partial Response – 1 %-35% Ph⁺ positive metaphases
 - Major Response – 0 %-35% Ph⁺ positive metaphases
 - Complete + Partial
 - Minor - > 35% Ph⁺ positive metaphases

41

Chronic Phase CML – 3 Month F/U

- Patients achieving a complete hematologic response are continued on their current medication at the same dose.
- Patients who fail to achieve a complete hematologic response are evaluated for compliance, drug-drug interaction and possibly mutational status but generally are switched to an alternate TKI as second line treatment.
- Other treatment options include evaluation and discussion of HSCT and clinical trial.

42

Chronic Phase CML – 6 Month F/U

- Patients achieving a complete hematologic response are continued on their current medication at the same dose.
- Patients who fail to achieve a complete hematologic response are evaluated for compliance, drug-drug interaction and possibly mutational status but generally are switched to an alternate TKI as second line treatment.
- Other treatment options include evaluation and discussion of HSCT and clinical trial.

43

Chronic Phase CML – 12 Month F/U

- Patients are again evaluated for a cytogenetic response
- Treatment is based on response
 - Complete – continue same med, same dose
 - Partial - continue same med at same dose. If taking imatinib, increase daily dose to 800mg po as tolerated.
 - Minor or no - evaluated for compliance, drug-drug interaction and possibly mutational status but generally are switched to an alternate TKI as second line treatment.
 - Other treatment options include evaluation and discussion of HSCT depending on response to secondary therapy or clinical trial.

44

CML Tx in Accelerated or Blast Phase

- About **85%** of patients are **diagnosed in the chronic phase**
- The **accelerated phase** of CML is characterized by **10% - 19% blasts in the WBC of peripheral blood** (WHO)
 - Note: There are alternative ways to define the accelerated phase proposed by Sokal et al., the International Bone Marrow Transplant Registry, and MD Anderson.
- The **blast phase**, also referred to as **blast crisis**, is most often defined as **>20% blasts WBC of peripheral blood**

45

Treatment for Accelerated or Blast Phase

- NCCN recommendations for patients who present with de novo accelerated or blast phase CML include
 - **Treatment with combination chemotherapy and TKI or a clinical trial.**
 - **For patients with a CML of the lymphoid lineage, ALL -type induction chemotherapy should be used in combination with a TKI. (Listing/description of ALL regimens to be provided as a handout.)**
 - **For patients with a CML of the myeloid lineage, AML-type induction chemotherapy should be used in combination with a TKI. (Listing/description of AML regimens to be provided as a handout.)**

46

FDA Approved CML Anti-Neoplastic Agents

| |
|-----------------------------|
| Clafen (Cyclophosphamide) |
| Cyclophosphamide |
| Cytarabine |
| Cytosar-U (Cytarabine) |
| Cytosan (Cyclophosphamide) |
| Dasatinib |
| Gleevec (Imatinib Mesylate) |
| Imatinib Mesylate |
| Neosar (Cyclophosphamide) |
| Nilotinib |
| Sprycel (Dasatinib) |
| Tarabine PFS (Cytarabine) |
| Tasigna (Nilotinib) |

47

CML Treatment Support Care Drugs

- **Growth Factors**
 - filgrastim (Neupogen®)
 - pegfilgrastim (Neulasta®)
- Diuretics (aldactone, hydrochlorothiazide [HCTZ]), steroids (prednisone 20mg/day x 3 for effusions)
- Topical steroids (hydrocortisone cream)
- Antidiarrheal agents (loperamide [Imodium®])
- Analgesics (acetaminophen, ibuprofen)

48

Primary Myelofibrosis

Table 5. Criteria for primary myelofibrosis (PMF)

Diagnosis requires meeting all 3 major criteria and 2 minor criteria

Major criteria

1. Presence of megakaryocyte proliferation and atypia,* usually accompanied by either reticulin or collagen fibrosis,
or,
in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by an increased bone marrow cellularity characterized by granulocytic proliferation and often decreased erythropoiesis (ie, prefibrotic cellular-phase disease)
2. Not meeting WHO criteria for polycythemia vera,† *BCR-ABL1*-positive chronic myelogenous leukemia,‡ myelodysplastic syndrome,§ or other myeloid disorders
3. Demonstration of *JAK2* V617F or other clonal marker (eg, *MPLW515K/L*),
or,
in the absence of the above clonal markers, no evidence that bone marrow fibrosis is secondary to infection, autoimmune disorder or other chronic inflammatory condition, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies||

Minor criteria

1. Leukoerythroblastosis¶
2. Increase in serum lactate dehydrogenase level¶
3. Anemia¶
4. Palpable splenomegaly¶

49

Vardiman JW et al. Blood, 2009; 114:937

Polycythemia Vera

Table 3. Criteria for polycythemia vera (PV)

Diagnosis requires the presence of both major criteria and one minor criterion or the presence of the first major criterion together with two minor criteria:

Major criteria

1. Hemoglobin > 18.5 g/dL in men, 16.5 g/dL in women or other evidence of increased red cell volume*
2. Presence of *JAK2* V617F or other functionally similar mutation such as *JAK2* exon 12 mutation

Minor criteria

1. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation
2. Serum erythropoietin level below the reference range for normal
3. Endogenous erythroid colony formation in vitro

50

Vardiman JW et al. Blood, 2009; 114:937

Essential Thrombocythemia

Table 4. Criteria for essential thrombocythemia (ET)

Diagnosis requires meeting all 4 criteria

1. Sustained platelet count $\geq 450 \times 10^9/L^*$
2. Bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased numbers of enlarged, mature megakaryocytes. No significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis.
3. Not meeting WHO criteria for polycythemia vera,† primary myelofibrosis,‡ *BCR-ABL1*-positive CML,§ or myelodysplastic syndrome,|| or other myeloid neoplasm.
4. Demonstration of *JAK2* V617F or other clonal marker, or in the absence of *JAK2* V617F, no evidence of reactive thrombocytosis¶.

51

Vardiman JW et al. Blood, 2009; 114:937

FDA Approved - Myeloproliferative Anti-Neoplastic Agents

| |
|--|
| ADE |
| Adriamycin PFS (Doxorubicin Hydrochloride) |
| Adriamycin RDF (Doxorubicin Hydrochloride) |
| Arsenic Trioxide |
| Cerubidine (Daunorubicin Hydrochloride) |
| Clafen (Cyclophosphamide) |
| Cyclophosphamide |
| Cytarabine |
| Cytosar-U (Cytarabine) |
| Cytosan (Cyclophosphamide) |
| Daunorubicin Hydrochloride |
| Doxorubicin Hydrochloride |
| Neosar (Cyclophosphamide) |
| Rubidomycin (Daunorubicin Hydrochloride) |
| Tarabine PFS (Cytarabine) |
| Trisenox (Arsenic Trioxide) |
| Vincasar PFS (Vincristine Sulfate) |
| Vincristine Sulfate |

52

Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1

Table B2: Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1

| WHO Preferred Term | ICD-O-3 |
|--|---------|
| Myeloid and lymphoid neoplasm with FGFR1 abnormalities | 9967/3 |
| Myeloid and lymphoid neoplasm with PDGFRA rearrangement | 9965/3 |
| Myeloid neoplasm with PDGFRB rearrangement | 9966/3 |

53


Myelodysplastic / Myeloproliferative Neoplasm

Table B3: Myelodysplastic / Myeloproliferative Neoplasms

| WHO Preferred Term | ICD-O-3 |
|--|---------------|
| Atypical chronic myeloid leukemia, BCR-ABL1 negative | 9876/3 |
| Chronic myelomonocytic leukemia | 9945/3 |
| Juvenile myelomonocytic leukemia | 9946/3 |
| Myelodysplastic/myeloproliferative neoplasm, unclassifiable | 9975/3 |
| Refractory anemia with ring sideroblasts | 9982/3 |

54

Chronic Myeloid Neoplasms



Myelodysplastic Syndromes

Table B4: Myelodysplastic Syndromes

| WHO Preferred Term | ICD-O-3 |
|---|---------|
| Myelodysplastic syndrome associated with isolated del(5q) | 9986/3 |
| Myelodysplastic syndrome, unclassifiable | 9989/3 |
| Refractory anemia | 9980/3 |
| Refractory anemia with excess blasts | 9983/3 |
| Refractory anemia with ring sideroblasts | 9982/3 |
| Refractory cytopenia of childhood | 9985/3 |
| Refractory neutropenia | 9991/3 |
| Refractory thrombocytopenia | 9992/3 |

Myelodysplastic Syndromes Treatment (PDQ®)

Updated: 04/13/2011

Myelodysplastic Syndromes: Comparison of the FAB and WHO Classifications

| FAB (1982) | WHO (1997) |
|---|---|
| Myelodysplastic Syndromes | |
| Refractory anemia. | Refractory anemia. |
| | Refractory cytopenia with multilineage dysplasia. |
| Refractory anemia with ringed sideroblasts. | Refractory anemia with ringed sideroblasts. |
| Refractory anemia with excess blasts. | Refractory anemia with excess blasts. |
| | Myelodysplastic syndrome, unclassifiable. |
| | Myelodysplastic syndrome associated with del(5q). |
| | Reclassified from MDS to: |
| Refractory anemia with excess blasts in transformation. | Acute Myeloid Leukemia identified as AML with multilineage dysplasia following a myelodysplastic syndrome. |
| Chronic myelomonocytic leukemia. | Myelodysplastic and Myeloproliferative Diseases |

AML = Acute Myeloid Leukemia; FAB = French-American-British classification scheme; MDS = Myelodysplastic Syndromes; WHO = World Health Organization.

57

MDS – 2 Classification Systems

- **De novo myelodysplastic syndrome**
 - Most MDS cases occur de novo with no known cause.
- **Secondary myelodysplastic syndrome**
 - MDS may be increased by exposure to a variety of agents including
 - Tobacco smoke.
 - Ionizing radiation.
 - Organic chemicals (e.g., benzene, toluene, xylene, and chloramphenicol).
 - Heavy metals.
 - Herbicides.
 - Pesticides.
 - Fertilizers.
 - Stone and cereal dusts.
 - Exhaust gases.
 - Nitro-organic explosives.
 - Petroleum and diesel derivatives.
 - Alkylating agents.
 - Marrow-damaging agents used in cancer chemotherapy.
 - Patients with documented exposure to such agents are referred to as having secondary MDS or treatment-related MDS and constitute as many as 30% of all patients with MDS. Secondary MDS typically has a poorer prognosis than does de novo MDS.

58

Myelodysplastic Syndrome Treatments

- **De Novo and Secondary Myelodysplastic Syndromes**
 - Supportive care with transfusion therapy
 - High-dose chemotherapy with stem cell transplant using stem cells from a donor.
 - Supportive care with growth factor therapy.
 - Chemotherapy with azacitidine, decitabine, or other anticancer drugs.
 - Supportive care with drug therapy.
 - A clinical trial of a new anticancer drug.
 - A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor.
 - A clinical trial of a combination of treatments.
 - A clinical trial of growth factor therapy.

59

Myelodysplastic Syndrome Treatments

- **Previously Treated Myelodysplastic Syndromes**
 - High-dose chemotherapy with stem cell transplant using stem cells from a donor.
 - Chemotherapy with azacitidine or decitabine.
 - Supportive care with transfusion therapy, growth factor therapy, and/or drug therapy.
 - A clinical trial of low-dose chemotherapy with stem cell transplant using stem cells from a donor.
 - A clinical trial of new drug therapy.
 - A clinical trial of a combination of treatments.
 - A clinical trial of growth factor therapy.

60

FDA Approved – Myelodysplastic Anti-Neoplastic Agents

| |
|--|
| ADE |
| Adriamycin PFS (Doxorubicin Hydrochloride) |
| Adriamycin RDF (Doxorubicin Hydrochloride) |
| Arsenic Trioxide |
| Cerubidine (Daunorubicin Hydrochloride) |
| Clafen (Cyclophosphamide) |
| Cyclophosphamide |
| Cytarabine |
| Cytosar-U (Cytarabine) |
| Cytosan (Cyclophosphamide) |
| Daunorubicin Hydrochloride |
| Doxorubicin Hydrochloride |
| Neosar (Cyclophosphamide) |
| Rubidomycin (Daunorubicin Hydrochloride) |
| Tarabine PFS (Cytarabine) |
| Trisenox (Arsenic Trioxide) |
| Vincasar PFS (Vincristine Sulfate) |
| Vincristine Sulfate |

61

Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

Table B5: Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

| WHO Preferred Term | ICD-O-3 |
|--|---------|
| Acute myeloid leukemias with recurrent genetic abnormalities | |
| Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 | 9911/3 |
| Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFβ-MYH11 | 9871/3 |
| Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | 9869/3 |
| Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 9896/3 |
| Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL | 9897/3 |
| Acute promyelocytic leukemia (AML with t(15;17)(q22;q12), PML/RARA | 9866/3 |
| | |
| Acute myeloid leukemia with myelodysplasia-related changes | 9895/3 |
| | |
| Therapy-related myeloid neoplasm | 9920/3 |

62

Table B5 continued

| WHO Preferred Term | ICD-O-3 |
|--|----------------|
| Acute myeloid leukemia, NOS | 9861/3 |
| Acute myeloid leukemia with minimal differentiation | 9872/3 |
| Acute myeloid leukemia without maturation | 9873/3 |
| Acute myeloid leukemia with maturation | 9874/3 |
| Acute myelomonocytic leukemia | 9867/3 |
| Acute erythroid leukemia | 9840/3 |
| Acute megakaryoblastic leukemia | 9910/3 |
| Acute basophilic leukemia | 9870/3 |
| Acute panmyelosis with myelofibrosis | 9931/3 |
| | |
| Myeloid sarcoma | 9930/3 |
| | |
| Myeloid proliferations related to Down syndrome | <i>No Code</i> |
| Transient abnormal myelopoiesis | 9898/1 |
| Myeloid leukemia associated with Down syndrome | 9898/3 |
| | |
| Blastic plasmacytoid dendritic cell neoplasm | 9727/3 |

63

AML Treatment

- Successful treatment of acute myeloid leukemia (AML) requires the control of bone marrow and systemic disease.
- The cornerstone of this strategy includes systemically administered combination chemotherapy.
- Treatment is divided into two phases:
 - remission induction (to attain remission)
 - postremission (to maintain remission).

64

FDA Approved AML Anti-Neoplastic Agents

| | |
|--|--|
| ADE | Cytoxan (Cyclophosphamide) |
| Adriamycin PFS (Doxorubicin Hydrochloride) | Daunorubicin Hydrochloride |
| Adriamycin RDF (Doxorubicin Hydrochloride) | Doxorubicin Hydrochloride |
| Arsenic Trioxide | Neosar (Cyclophosphamide) |
| Cerubidine (Daunorubicin Hydrochloride) | Rubidomycin (Daunorubicin Hydrochloride) |
| Clafen (Cyclophosphamide) | Tarabine PFS (Cytarabine) |
| Cyclophosphamide | Trisenox (Arsenic Trioxide) |
| Cytarabine | Vincasar PFS (Vincristine Sulfate) |
| Cytosar-U (Cytarabine) | Vincristine Sulfate |

65

2010 Hematopoietic and Lymphoid Multiple Primary Rules and Histology Coding Rules



66

How to Use and Follow the Rules




67


Rule Basics

1. Is the condition reportable?
2. How many cases do I abstract?
3. How do I code the primary site?
4. How do I code the histology?
5. How do I code the grade?

68



Case Reportability and MP Rules



Case Reportability Instructions

- 10 Case Reportability Instructions
- Follow the instructions
- Not hierarchical
- Not “rules”
- Text

71

Multiple Primary – M Rules

- 3 formats
 - Text
 - Matrix
 - Flowchart
- Use Multiple Primary Rules and Database
 - First Apply the Rules
 - If necessary – Apply Multiple Primary Calculator
- DO NOT GO DIRECTLY to the Database

72

SEER Surveillance Epidemiology and End Results
providing information on cancer statistics to help reduce the burden of this disease on the U.S. population

Home About SEER Cancer Statistics Datasets & Software Publications Information for Cancer Registrars

Home > Registrars > Hematopoietic & Lymphoid Neoplasm Project

Information for Cancer Registrars

Hematopoietic & Lymphoid Neoplasm Project
Version 1.6.2 released January 4, 2011

New reportability instructions and data collection rules for hematopoietic and lymphoid neoplasms go into effect for cases diagnosed beginning January 1, 2010. These instructions and rules were developed by the Hematopoietic Working Group. Two tools have been developed for use beginning in 2010.

- The Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual
- The Hematopoietic Database

The coding manual is embedded in the Hematopoietic Database (Hematopoietic DB). This manual contains reportability instructions and rules for determining the number of primaries, the primary site and histology, and the cell lineage or phenotype. The manual also includes several appendices. Use the instructions and rules within the manual first. The Hematopoietic DB is used when the rules specifically instruct the abstractor to refer to the DB or when the registrar has used all of the rules in the manual.

The Hematopoietic DB is an electronic tool developed to assist in screening for reportable cases and determining reportability requirements. The database contains abstracting and coding information for all hematopoietic and lymphoid neoplasms (9590/3-9992/3).

Prior to using either the manual or the Hematopoietic DB, view the hematopoietic and lymphoid neoplasm [educational presentations](#). These presentations cover essential topics such as:

- Disease presentation and the diagnostic process
- The lineages of hematopoietic and lymphoid neoplasms
- How to move through the rules and the database
- How to use the rules
- Using the database to its fullest potential
- How to use the electronic manual efficiently

For questions about the database and manual, [Ask a SEER Registrar](#).

Download the Hematopoietic Database version 1.6.2 (includes coding manual)

Download the installation program for Hematopoietic Database and Coding Manual [[HemaDB_1_6_2.exe](#)]. Refer to the [Revision History](#) and the [ReadMe.txt](#) for the list of changes to the manual and software.

The coding manual is also available to download separately: [Hematopoietic_Instructions_and_Rules.pdf](#) (4.1 MB)

[Sign Up for E-mail Updates](#)

73

NCI SEER Hematopoietic Database

Hematopoietic Database Version 1.6.2, Data updated: 3/30/2010

NATIONAL INSTITUTES OF HEALTH NATIONAL CANCER INSTITUTE

Hematopoietic Database


Enter search term or code (xxxxx)

Search Clear


Display Codes... Multiple Primaries Calculator... Hemato Manual

74

NCI SEER Hematopoietic Database



NCI SEER Hematopoietic Database



Appendix F
Master Code Lists

Table F1: WHO/ICD-O-3 Master List of Histology Codes - Alphabetic List

2010 WHO Only: New histology terms and codes published in the *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, 4th Edition. These codes are not in ICD-O-3 or the ICD-O-3 errata.
ICD-O-3 Only: The histology term and code are published only in ICD-O-3
WHO and ICD-O-3: The histology term is the WHO preferred term for that neoplasm; the WHO and ICD-O-3 preferred histology terms may not be the same, but the codes for this neoplasm are published in both WHO and in ICD-O-3.

| Histologic Term | 2010 WHO Only | ICD-O-3 Only | WHO and ICD-O-3 |
|---|---------------|--------------|-----------------|
| Acute basophilic leukemia | | | 9870/3 |
| Acute biphenotypic leukemia | | 9805/3 | |
| Acute erythroid leukemia | | | 9840/3 |
| Acute megakaryoblastic leukemia | | | 9910/3 |
| Acute monoblastic and monocytic leukemia | | | 9891/3 |
| Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13):RBM15-MKL1 | 9911/3 | | |
| Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22):CBFB/MYH11 | | | 9871/3 |
| Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2):RPN1-EVT1 | 9869/3 | | |
| Acute myeloid leukemia with maturation | | | 9874/3 |
| Acute myeloid leukemia with minimal differentiation | | | 9872/3 |
| Acute myeloid leukemia with mutated CEBPA | | | 9861/3 |
| Acute myeloid leukemia with mutated NPM1 | | | 9861/3 |
| Acute myeloid leukemia with myelodysplasia-related changes | | | 9895/3 |
| Acute myeloid leukemia with t(6;9)(p23;q34):DEK-NUP214 | 9865/3 | | |
| Acute myeloid leukemia with t(8;21)(q22;q22):RUNX1-RUNX1T1 | | | 9896/3 |
| Acute myeloid leukemia with t(9;11)(q22;q23):MLL19-MLL | | | 9897/3 |
| Acute myeloid leukemia without maturation | | | 9873/3 |
| Acute myeloid leukemia, NOS | | | 9861/3 |
| Acute myelomonocytic leukemia | | | 9867/3 |
| Acute panmyelosis with myelofibrosis | | | 9931/3 |
| Acute promyelocytic leukemia (AML with t(15;17)(q22;q12):PML-RARA | | | 9866/3 |
| Acute undifferentiated leukemia | | | 9801/3 |
| Adult T-cell leukemia/lymphoma | | | 9827/3 |
| Aggressive NK-cell leukemia | | | 9948/3 |
| ALK positive large B-cell lymphoma | 9737/3 | | |
| Alpha heavy chain disease | | | 9762/3 |
| Anaplastic large cell lymphoma, ALK negative | | | 9702/3 |
| Anaplastic large cell lymphoma, ALK positive | | | 9714/3 |

Version 1.6 (June 2010)

Effective with Cases Diagnosed 1/1/2010 and After

110

NCI SEER Hematopoietic Database

The screenshot shows a search results page for 'polycythemia vera'. The search found 13 results. The top result is 'Polycythemia vera', with ICD-O-3 Code 9950/3 and Reportable status 'Yes'. Below the search results, there is a detailed view for 'Polycythemia vera' (ICD-O-3 Code: 9950/3, Preferred Term: Polycythemia vera). The definition states: 'A disease in which there are too many red blood cells in the bone marrow and blood, causing the blood to thicken. The number of white blood cells and platelets may also increase. The extra blood cells may collect in the spleen and cause it to become enlarged. They may also cause bleeding problems and make clots form in blood vessels. PV arises in clonal hematopoietic stem cell, characterized by increased RBC production independent of mechanisms that normally regulate erythropoiesis.' Under 'Alternate Names', a list includes: Chronic erythremia, Erythrocytosis, Erythrocytosis megalosplenia, Myeloproliferative polycythemia, Osler-Vaquez disease, PV, Polycythemia vera, Polycythemia rubra vera, Polycythemia with chronic cyanosis, Primary polycythemia, Proliferative polycythemia, Spontaneous polycythemia, Splenomegaly polycythemia, and Vaquez-Osler's disease. At the bottom, there are checkboxes for 'Display' and 'Print Screen'.

NCI SEER Hematopoietic Database

Polycythemia vera

File Help

ICD-O3 Code: Preferred Term
99503 Polycythemia vera

Alternate Names
Chronic erythremia
Cytogenic polycythemia
Erythremia
Erythrocytosis myeloides/vera

Definitions Primary Site
C421
A disease in which there are too many red blood cells in the bone marrow and blood, causing the blood to thicken. The number of white blood cells and platelets may also increase. The extra blood cells may collect in the spleen and cause it to become enlarged. They may also cause bleeding problems and make clots form in blood vessels. PV arises in clonal hematopoietic stem cell, characterized by increased RBC production independent of mechanisms that normally regulate erythropoiesis.

Definitive Diagnostic Methods
Clinical diagnosis, JAK2

Disease Genetics Data
Janus kinase-2, JAK2

Disease Immunophenotyping
No immunophenotype features have been reported

Treatments (For more Treatment information, see [SEERs](#))
Chemotherapy

Transformations
Acute myeloid leukemia, Megakaryoblastic leukemia, Myelodysplastic syndrome

Back to Results Display Abstracts Notes Home

79

NCI SEER Hematopoietic Database

Langerhans cell histiocytosis, disseminated

File Help

ICD-O3 Code: Preferred Term
97543 Langerhans cell histiocytosis, disseminated

Alternate Names
No Alternate Names found

Definitions Primary Site
N/A, see Help for details
Multigorgan involvement
Neoplastic proliferation of Langerhans cells, with expression of CD1a, S-100 protein, and presence of Birbeck granules

Definitive Diagnostic Methods
None

Disease Genetics Data
None

Disease Immunophenotyping
None

Treatments (For more Treatment information, see [SEERs](#))
No Treatments Found

Transformations
None

Back to Results Display Abstracts Notes Home

80

NCI SEER Hematopoietic Database

Langerhans cell histiocytosis, disseminated

File Help

ICD-O.3 Code Preferred Term

Now grouped and coded this neoplasm under new histology term and code Langerhans cell histiocytosis (9751/3). Do not use this code for cases diagnosed on or after 1/1/2010. For information on the coding and abstracting of this disease, see 9751/3.

Back to Results Hide Abstractor Notes Home

81

CSv2 Coding Instructions, CSv02.03.02

HemeRetic

82

HemeRetc

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

- M9733, 9740, 9742, 9750, 9758, 9760, 9762, 9764, 9766, 9800, 9801, 9805-9809, 9811, 9818, 9820, 9823 [C420, C421, or C424 ONLY]
- 9826, 9827 [C420, C421, or C424 ONLY], 9831-9837, 9840, 9860-9861, 9863, 9865-9867, 9869-9876, 9891, 9895-9898, 9910, 9920, 9930-9931, 9940, 9945-9946, 9948, 9950, 9960-9967, 9970, 9971, 9975, 9980, 9982-9987, 9989, 9991-9992 See site exceptions below
- Schema includes only preferred terms from ICD-O-3
- Plasmacytomas (9731 and 9734) and Multiple Myeloma (9732), except for cases with primary site C441, C690 and C695-C696, have been moved to the Myeloma/PlasmaCellDisorder schema in V2020
- 9733 Plasma cell leukemia [except C441, C690, C695-C696]
- 9740 Mast cell sarcoma
- 9741 Malignant mastocytosis
- 9742 Mast cell leukemia
- 9750 Malignant histiocytosis
- 9752 Langerhans cell histiocytosis, unifocal* (see new reportable code 975113)
- 9753 Langerhans cell histiocytosis, multifocal* (see new reportable code 975113)
- 9754 Langerhans cell histiocytosis disseminated
- 9755 Histiocytic sarcoma
- 9756 Langerhans cell sarcoma
- 9757 Interdigitating dendritic cell sarcoma
- 9758 Follicular dendritic cell sarcoma
- 9760 Immunoproliferative disease, NOS
- 9761 Waldenström macroglobulinemia
- 9762 Heavy chain disease, NOS
- 9764 Immunoproliferative small intestinal disease
- 9765 Monoclonal gammopathy of undetermined significance*
- 9766 Angiocentric immunoproliferative lesion*
- 9767 Angioimmunoblastic lymphadenopathy*
- 9768 T-gamma lymphoproliferative disease*
- 9769 Immunoglobulin deposition disease*
- 9800 Leukemia, NOS
- 9801 Acute leukemia, NOS
- 9805 Acute biphenotypic leukemia
- 9820 Lymphoid leukemia, NOS [except C441, C690, C695-C696]
- 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma [C420, C421, or C424 ONLY]
- 9826 B-cell chronic lymphocytic leukemia [except C441, C690, C695-C696]
- 9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive) [C420, C421, or C424 ONLY]
- 9832 Prolymphocytic leukemia, NOS [except C441, C690, C695-C696]
- 9833 Prolymphocytic leukemia, B-cell type [except C441, C690, C695-C696]
- 9834 Prolymphocytic leukemia, T-cell type [except C441, C690, C695-C696]
- 9835 Precursor cell lymphoblastic leukemia, NOS [except C441, C690, C695-C696]
- 9836 Precursor B-cell lymphoblastic leukemia [except C441, C690, C695-C696]
- 9837 Precursor T-cell lymphoblastic leukemia [see 9837 below, new definition]
- 9840 Acute myeloid leukemia, M5 type
- 9860 Myeloid leukemia, NOS
- 9861 Acute myeloid leukemia, NOS
- 9863 Chronic myeloid leukemia
- 9866 Acute promyelocytic leukemia
- 9867 Acute myelomonocytic leukemia
- 9870 Acute basophilic leukemia
- 9871 Acute myeloid leukemia with abnormal marrow, eosinophils
- 9872 Acute myeloid leukemia, minimal differentiation
- 9873 Acute myeloid leukemia without maturation
- 9874 Acute myeloid leukemia with maturation
- 9875 Chronic myelogenous leukemia, BCR/ABL positive
- 9876 Atypical chronic myeloid leukemia BCR/ABL negative
- 9891 Acute monocytic leukemia
- 9895 Acute myeloid leukemia with multilineage dysplasia
- 9896 Acute myeloid leukemia, t(8;21)(q22;q22)
- 9897 Acute myeloid leukemia, 11q23 abnormalities
- 9910 Acute megakaryoblastic leukemia
- 9920 Therapy-related acute myeloid leukemia, NOS
- 9920 Myeloid sarcoma
- 9931 Acute paraneoplastic myelofibrosis
- 9940 Hairy cell leukemia
- 9945 Chronic myelomonocytic leukemia, NOS
- 9946 Juvenile myelomonocytic leukemia
- 9948 Aggressive NK-cell leukemia

- 9982 Refractory anemia with sideroblasts
- 9983 Refractory anemia with excess blasts
- 9984 Refractory anemia with excess blasts in transformation
- 9985 Refractory cytopenia with multilineage dysplasia
- 9986 Myelodysplastic syndrome with 5q deletion (5q-) syndrome
- 9987 Therapy-related myelodysplastic syndrome, NOS
- 9989 Myelodysplastic syndrome, NOS
- The following ICD-O codes were added to the reportable list for Hematopoietic diseases. These are from the "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 3rd edition" publication, which was released in 2008. These new codes have been incorporated into the new Hematopoietic and Lymphoid Neoplasm MPH rules. Use these only for cases diagnosed on January 1, 2010 and forward.
- 9751 Langerhans cell histiocytosis, NOS
- 9806 Mixed phenotype acute leukemia with t(9;22)(q34;q11.2), BCR-ABL1
- 9807 Mixed phenotype acute leukemia with t(11q23); MLL, rearranged
- 9808 Mixed phenotype acute leukemia, B/myeloid, NOS
- 9809 Mixed phenotype acute leukemia, T/myeloid, NOS
- 9811 B lymphoblastic leukemia/lymphoma, NOS [C420, C421, or C424 ONLY]
- 9812 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2), BCR-ABL1 [C420, C421, or C424 ONLY]
- 9813 B lymphoblastic leukemia/lymphoma with t(11q23); MLL rearranged [C420, C421, or C424 ONLY]
- 9814 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) [C420, C421, or C424 ONLY]
- 9815 B lymphoblastic/lymphoma with hyperdiploidy [C420, C421, or C424 ONLY]
- 9816 B lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL) [C420, C421, or C424 ONLY]
- 9817 B lymphoblastic/lymphoma with t(5;14)(q31;q32); ILL-3/IGH [C420, C421, or C424 ONLY]
- 9818 B lymphoblastic/lymphoma with t(1;19)(q23;p13.3), E2A-PBX1 (TCF3-PBX1) [C420, C421, or C424 ONLY]
- 9831 T-cell large granular lymphocytic leukemia [except C441, C690, C695-C696]
- 9837 T lymphoblastic leukemia/lymphoma [C420, C421, or C424 ONLY]
- 9865 Acute myeloid leukemia with t(6;9)(q23;q34) DEK-NUP214
- 9869 Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1EV1
- 9868 Myeloid leukemia associated with Down Syndrome
- 9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
- 9965 Myeloid and lymphoid neoplasms with PDGFRB rearrangement
- 9966 Myeloid neoplasm with PDGFRB rearrangement
- 9967 Myeloid and lymphoid neoplasm with FGF11 abnormalities
- 9971 Polymorphic PTLD
- 9975 Myeloproliferative neoplasm, unclassifiable
- 9991 Refractory neutropenia
- 9992 Refractory thrombocytopenia
- *Usually considered of uncertain/borderline behavior
- Note: AJCC does not define TNM staging for this site

[CS Tumor Size](#) = 988
[CS Extension](#)
[CS Tumor Size/Ext Eval](#) = 9
[CS Lymph Nodes](#)
[CS Lymph Nodes Eval](#) = 9
[Regional Nodes Positive](#) = 99
[Regional Nodes Examined](#) = 99
[CS Mets at DX](#)
[CS Mets Eval](#) = 9
[CS Site-Specific Factor 1](#)
 JAK2 (also known as Janus Kinase 2 and JAK2 Exon 12)
[CS Site-Specific Factor 2](#) = 988
[CS Site-Specific Factor 3](#) = 988
[CS Site-Specific Factor 4](#) = 988
[CS Site-Specific Factor 5](#) = 988
[CS Site-Specific Factor 6](#) = 988
[CS Site-Specific Factor 7](#) = 988
[CS Site-Specific Factor 8](#) = 988
[CS Site-Specific Factor 9](#) = 988
[CS Site-Specific Factor 10](#) = 988
[CS Site-Specific Factor 11](#) = 988
[CS Site-Specific Factor 12](#) = 988
[CS Site-Specific Factor 13](#) = 988
[CS Site-Specific Factor 14](#) = 988
[CS Site-Specific Factor 15](#) = 988
[CS Site-Specific Factor 16](#) = 988
[CS Site-Specific Factor 17](#) = 988
[CS Site-Specific Factor 18](#) = 988
[CS Site-Specific Factor 19](#) = 988
[CS Site-Specific Factor 20](#) = 988
[CS Site-Specific Factor 21](#) = 988
[CS Site-Specific Factor 22](#) = 988
[CS Site-Specific Factor 23](#) = 988
[CS Site-Specific Factor 24](#) = 988
[CS Site-Specific Factor 25](#) = 988
[Histology Inclusion Table AJCC 7th ed.](#) = NA
[Histology Exclusion Table AJCC 6th ed.](#) = NA
[AJCC TNM 7 Stage](#) = NA
[AJCC TNM 6 Stage](#) = NA
[Summary Stage](#)

[Decision Info: List of Schemas](#)

HemeRetic

CS Extension

• Note: Plasmacytomas (9731 and 9734) and Multiple Myeloma (9732) have been moved to the MyelomaPlasmaCellDisorder schema effective with CS version 2.0203

| Code | Description | TNM 7 Map | TNM 6 Map | S577 Map | SS2000 Map |
|------|--|-----------|-----------|----------|------------|
| 100 | Localized disease (Single/solitary/unifocal/isolated) May be coded for: Mast cell sarcoma (9740) Malignant histiocytosis (9750) Langerhans cell histiocytosis (9751) Histiocytic sarcoma (9755) Langerhans cell sarcoma (9756) Dendritic cell sarcoma (9757, 9758) Myeloid sarcoma (9630) | NA | NA | L | L |
| 800 | Systemic disease (All histologies including those in 100) | NA | NA | D | D |
| 999 | Unknown; extension not stated Primary tumor cannot be assessed Not documented in patient record | NA | NA | D | D |

FCDS Required Site-Specific Factors

FCDS-Required ONLY SSFs for FCDS and CER
FCDS Staff will Collect the CER Items

| Schema Name | FCDS Required | CER Required | CoC Additional Required |
|-------------|---------------|--------------|-------------------------------|
| HemeRetic | SSF1 | Non-Standard | SSF1 |
| CML | Non-Standard | BCR-ABL | no |

Collaborative Stage for TNM 7 - Revised 11/13/2010 [Schema]

HemeRetic

CS Site-Specific Factor 1

JAK2 (also known as Janus Kinase 2 and JAK2 Exon 12)

- Note 1: Janus Kinase 2 (JAK2, JAK 2) is a gene mutation that increases susceptibility to several myeloproliferative neoplasms (MPNs). Testing for the JAK2 mutation is done on whole blood. Nearly all people with polycythemia vera and about half of those with essential thrombocythemia and primary myelofibrosis have the mutation.
- Note 2: JAK2 is used primarily for the following histologies: Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. Its usage continues to increase and may be used for other histologies in the future. Record JAK2 for any hematopoietic/reticuloendothelial disease even if it is not one of these three specific histologies.
- Note 3: If JAK2 test result is positive, NOS, use code 850.

| Code | Description |
|------|--|
| 000 | JAK2 result stated as negative |
| 010 | JAK2 positive for mutation V617F in exon 14 |
| 020 | JAK2 positive for mutation of exon 12 |
| 800 | JAK2 positive for other specified mutation |
| 810 | JAK2 positive for more than one mutation |
| 850 | JAK2 positive NOS; specific mutation(s) not stated |
| 888 | OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site |
| 988 | Not applicable: information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.) |
| 997 | Test ordered, results not in chart |
| 998 | Test not done (test not ordered and not performed) |
| 999 | Unknown or no information Not documented in patient record |

REMINDER

2010 Text Documentation Requirements 2011 FCDS DAM / Appendix K, Oct 2011

Text documentation should always include the following components:

- ✓ Date(s) – include date(s) references – so the reviewer can determine event chronology
- ✓ Location – include facility/physician/other location where the event occurred (test/study/treatment/other)
- ✓ Description – include description of the event (test/study/treatment/other) – include positive/negative results
- ✓ Details – include as much detail as possible – document treatment plan even if treatment is not given as planned

89

References & More Information

- **WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 4th edition**, S. Swerdlow, E. Campo, N. Lee Harris, E. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman, IAR C, Lyon, France, 2008
- **2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual**, C. Hahn Johnson, M. Adamo, S. Peace, NCI SEER, 2009
- **Classification, Characteristics, and Behavior of Myeloid Neoplasms**, G.M. Dores, NCI, 2010
- **North Carolina Central Cancer Registry CER Mini-Guidebook, 2011**
- **Louisiana Tumor Registry Presentation (CML Treatment Guidelines), 2011;** Colleen Lemoine, APRN, MN, AOCN, RN-BC
- **Advances in Understanding and Management of Myeloproliferative Neoplasms**, Alessandro M. Vannucchi, Paola Guglielmelli and Ayalew Tefferi, *CA Cancer J Clin* 2009;59;171-191; Apr 15, 2009
- **NCCN Treatment Guidelines for CML, 2011**
- **The Chronic Myeloproliferative Disorders and the Myelodysplastic/Myeloproliferative Disorders, Chapter 14**
- **90 The Myelodysplastic Syndromes, Chapter 15**